Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat

BMC Cardiovascular Disorders

Volumn 14, Issue 1, 2014, Pages

  Zhang, Yan ^a   Liu, Jun ^a   Li, Sha ^a   Xu, Rui Xia ^a   Sun, Jing ^a   Tang, Yue ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Acute myocardial infarction; PCSK9; Rat

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1ALPHA; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROTEIN PCSK9; SERINE PROTEINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; PCSK9 PROTEIN, RAT;

ACUTE HEART INFARCTION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SHAM PROCEDURE; TISSUE SECTION; UPREGULATION; ANIMAL; BLOOD; HEART INFARCTION; LEUKOCYTE COUNT; LIVER; LIVER CELL; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTES; LEUKOCYTE COUNT; LIPIDS; LIVER; MALE; MYOCARDIAL INFARCTION; RATS, SPRAGUE-DAWLEY; RECEPTORS, LDL; RNA, MESSENGER; SERINE ENDOPEPTIDASES; UP-REGULATION;

EID: 84964695749     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-14-192     Document Type: Article

References (38)

1. Cariou B, May CL, Costet P: Clinical aspects of PCSK9. Atherosclerosis 2011, 216:258-265.
2. Homer VM, Marais AD, Charlton F, Laurie AD, Hurndell N, Scott R, Mangili F, Sullivan DR, Barter PJ, Rye KA, George PM, Lambert G: Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 2008, 196:659-666.
3. Wu NQ, Guo YL, Xu RX, Liu J, Zhu CG, Jiang LX, Li JJ: Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: laboratory findings and response to lipidlowering drugs. Clin Lab 2013, 59:901-907.
4. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG: Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012, 97:3956-3964.
5. Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, Seidah NG, Prat A: Gene Inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 2012, 125:894-901.
6. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
7. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD: Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006, 116:2995-3005.
8. Urban D, Pöss J, Böhm M, Laufs U: Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis. J Am Coll Cardiol 2013, 62:1401-1408.
9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
10. Balci B: The modification of serum lipids after acute coronary syndrome and importance in clinical practice. Curr Cardiol Rev 2011, 7:272-276.
11. Liu J, Guo YL, Xu RX, Li JJ: Rapid effects of different lipid-lowering drugs on PCSK9 in humans. Clin Lipidol 2013, 8:519-524.
12. Troutt JS, Alborn WE, Cao G, Konrad RJ: Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res 2010, 51:345-351.
13. Browning JD, Horton JD: Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010, 51:3359-3363.
14. Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, Hu Y, Haas JV, Troutt JS, Pickard RT, Darling R, Konrad RJ, Zhou H, Cao G: Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010, 213:632-636.
15. Miyazawa H, Honda T, Miyauchi S, Domon H, Okui T, Nakajima T, Tabeta K, Yamazaki K: Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration. Clin Chim Acta 2012, 413:154-159.
16. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C: Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 2008, 374:341-344.
17. Le Bras M, Roquilly A, Deckert V, Langhi C, Feuillet F, Sébille V, Mahé PJ, Bach K, Masson D, Lagrost L, Costet P, Asehnoune K, Cariou B: Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab 2013, 98:E732-E736.
18. Chen SN, Ballantyne CM, Gotto AM Jr, Tan Y, Willerson JT, Marian AJ: A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005, 45:1611-1619.
19. Duan HF, Wang H, Yi J, Liu HJ, Zhang QW, Li LB, Zhang T, Lu Y, Wu CT, Wang LS: Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Hum Gene Ther 2007, 18:1119-1128.
20. Guo YL, Liu J, Xu RX, Zhu CG, Wu NQ, Jiang LX, Li JJ: Short-Term Impact of Low-Dose Atorvastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9. Clin Drug Investig 2013, 33:877-883.
21. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW: Sterol dependent regulation of proprotein convertase subtilisin/kexin type 9 by sterol regulatory element binding-protein 2. J Lipid Res 2008, 49:399-409.
22. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J: Hepatocyte nuclear factor 1 alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009, 284:28885-28895.
23. Li JJ: Inflammation in coronary artery diseases. Chin Med J (Engl) 2011, 124:3568-3575.
24. Klingenberg R, Luscher TF: Inflammation in coronary artery disease and acute myocardial infarction-is the stage set for novel therapies? Curr Pharm Des 2012, 18:4358-4369.
25. Blancke F, Claeys MJ, Jorens P, Vermeiren G, Bosmans J, Wuyts FL, Vrints CJ: Systemic inflammation and reperfusion injury in patients with acute myocardial infarction. Mediat Inflamm 2005, 2005:385-389.
26. Yavuz MT, Yavuz O, Yazici M, Guler S, Ozhan H, Albayrak S, Coskun A: Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis inpatients with severe coronary stenosis. Scand J Clin Lab Invest 2006, 66:523-534.
27. Li JJ, Wang HR, Huang CX, Xue JL, Li GS: Enhanced response of blood monocytes to C-reactive protein in patients with unstable angina. Clin Chim Acta 2004, 352:127-133.
28. Li JJ, Fang CH, Cheng MZ, Chen X, Lee SW: Activation of nuclear factor-?B and correlation with elevated plasma C-reactive protein in patients with unstable angina. Heart Lung Circ 2004, 13:173-178.
29. Altun B, Turkon H, Tasolar H, Beggi H, Altun M, Temiz A, Gazi E, Barutcu A, Bekler A, Colkesen Y: The relationship between high-sensitive troponin T, neutrophil lymphocyte ratio and SYNTAX Score. Scand J Clin Lab Invest 2014, 74:108-115.
30. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, Hamm CW, CAPTURE Investigators: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440-1445.
31. Zhu XY, Zhang ZL, Li P, Liang WY, Feng XR, Liu ML: Shenyuan, an extract of American Ginseng and Corydalis Tuber formula, attenuates cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and oxidative stress in a porcine model of acute myocardial infarction. J Ethnopharmacol 2013, 150:672-681.
32. Rousselet E, Marcinkiewicz J, Kriz J, Zhou A, Hatten ME, Prat A, Seidah NG: PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res 2011, 52:1383-1391.
33. Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS, Liu LS: PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol Cell Biochem 2012, 359:347-358.
34. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169-1196.
35. Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL: Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 2012, 220:381-386.
36. Berti V, Sciagrà R, Acampa W, Ricci F, Cerisano G, Gallicchio R, Vigorito C, Pupi A, Cuocolo A: Relationship between infarct size and severity measured by gated SPECT and long-term left ventricular remodelling after acute myocardial infarction. Eur J Nucl Med Mol Imaging 2011, 38:1124-1131.
37. Ballantyne CM, Pitt B, Loscalzo J, Cain VA, Raichlen JS: Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). Am J Cardiol 2013, 111:506-509.
38. Ferrières J, Cambou JP, Guéret P, Boutalbi Y, Lablanche JM, Hanania G, Genès N, Cantet C, Danchin N: Effect of early initiation of statins on survival in patients with acute myocardial infarction (the USIC 2000 Registry). Am J Cardiol 2005, 95:486-489.